Can-Fite BioPharma (CANF)
XASE:CANF
Total Valuation
Can-Fite BioPharma has a market cap or net worth of $6.56M. The enterprise value is $7.87B.
Market Cap$6.56M
Enterprise Value$7.87B
Share Statistics
Can-Fite BioPharma has 2,142,545 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,142,545
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Can-Fite BioPharma’s return on equity (ROE) is -1.77 and return on invested capital (ROIC) is -146.65%.
Return on Equity (ROE)-1.77
Return on Assets (ROA)-1.04
Return on Invested Capital (ROIC)-146.65%
Return on Capital Employed (ROCE)-1.48
Revenue Per Employee81.64K
Profits Per Employee-1.98M
Employee Count5
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Can-Fite BioPharma is ―. Can-Fite BioPharma’s PEG ratio is -0.00033.
PE Ratio―
PS Ratio8.07
PB Ratio0.59
Price to Fair Value0.59
Price to FCF-0.37
Price to Operating Cash Flow-801.02
PEG Ratio-0.00033
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 408.21K and earned -9.91M in profits. Earnings per share was -12.03.
Revenue408.21K
Gross Profit384.02K
Operating Income-10.03M
Pretax Income-9.91M
Net Income-9.91M
EBITDA-10.00M
Earnings Per Share (EPS)-12.03
Cash Flow
In the last 12 months, operating cash flow was -8.35M and capital expenditures -2.00K, giving a free cash flow of -8.36M billion.
Operating Cash Flow-8.35M
Free Cash Flow-8.36M
Free Cash Flow per Share-3.90
Dividends & Yields
Can-Fite BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change-89.77%
50-Day Moving Average4.09
200-Day Moving Average9.72
Relative Strength Index (RSI)36.05
Average Volume (3m)258.05K
Important Dates
Can-Fite BioPharma upcoming earnings date is Aug 27, 2026, Before Open (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateAug 27, 2026
Ex-Dividend Date―
Financial Position
Can-Fite BioPharma as a current ratio of 3.46, with Debt / Equity ratio of 2.15%
Current Ratio3.46
Quick Ratio3.46
Debt to Market Cap0.02
Net Debt to EBITDA0.55
Interest Coverage Ratio-710.72
Taxes
In the past 12 months, Can-Fite BioPharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Can-Fite BioPharma EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.24.
EV to Sales-5.29
EV to EBITDA0.22
EV to Free Cash Flow0.24
EV to Operating Cash Flow0.24
Balance Sheet
Can-Fite BioPharma has $6.46M in cash and marketable securities with $90.00K in debt, giving a net cash position of $6.37M billion.
Cash & Marketable Securities$6.46M
Total Debt$90.00K
Net Cash$6.37M
Net Cash Per Share$2.97
Tangible Book Value Per Share$6.79
Margins
Gross margin is 100.00%, with operating margin of -2456.80%, and net profit margin of -2426.67%.
Gross Margin100.00%
Operating Margin-2456.80%
Pretax Margin-2426.67%
Net Profit Margin-2426.67%
EBITDA Margin-2450.87%
EBIT Margin-2456.80%
Analyst Forecast
The average price target for Can-Fite BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―